|
The Board of Henderson Morley plc (“Henderson Morley” or
“the Company”), the AIM listed drug discovery company, is
pleased to provide the market and its shareholders with an
update in respect of the studies relating to the Koi Carp
vaccine following the announcement made on 3 October 2006.
These studies were designed to establish if the vaccine
candidate is able to boost the immune system of vaccinated
fish and included dose ranging studies to determine at
what dose the vaccine should be administered. A successful
vaccine should enable Koi exposed to virus, to mount a
successful immune response against KHV and thus prevent
disease. These studies examined antibody responses to
vaccination also known as antigenicity studies.
The antigenicity studies of the Koi herpes vaccine
candidate have now been completed. The data has been
analysed and the Board is pleased to announce that 100% of
the vaccine recipients tested have produced a significant
immune response.
This level of immunity is a very good indicator of a
successful vaccine being developed. Further field studies
are ongoing and the Company will keep shareholders
informed of progress in due course.
|
